Respiratory tract infections are very common worldwide. The human airway is subdivided into upper and lower airways. Influenza viruses have different tropisms for different cell types within the airways. Notably, airway inflammation is common in respiratory diseases, thus requiring effective anti-inflammatory compounds. Although cell culture, organoid or animal models provide promising insights into the development of new compounds, they also have limitations. The development of human lower airway models facilitates the study of mechanisms underlying the inflammatory response and provides an attractive tool for drug development in inflammatory respiratory diseases.
Cell models | Animal models |
|
|
Fig.1 Inadequacies of the traditional model. (Creative Biolabs)
Fig.2 Typical applications. (Creative Biolabs)
Preliminary data exist demonstrating that ex vivo human lung tissue models can be used to study the effect of allergens and other inflammatory stimuli on selected cytokine responses. As a world-leading supplier of ex vivo models, our vision is to develop ex vivo human lower airways models, which are suitable for on-target validation. We are committed to advancing the research and preclinical drug development of inflammatory mechanisms related to airway disease. If you have any questions, please do not hesitate to contact us for more details.
More information on the models can be obtained through the links below: